Verdict: Side-by-side breakdown using the Bull Rankings model. BIIB scored 37.7, LLY scored 77.3 — LLY leads.
Compare another set
Different reporting periods. LLY's fundamentals are as of June 2026, but BIIB's are as of March 2026 — a 3-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
BIIB
Biogen Inc.
Drug Manufacturers - General · Quality-Growth
37.7
$225.71 · $33.3B
fundamentals as of
Score gap
39.6
LLY leads
LLY
Eli Lilly and Company
Drug Manufacturers - General · Quality-Growth
77.3
$1,179.27 · $1.1T
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestLLY39.6x
Fastest growthLLY+49.6%
Strongest balance sheetBIIB0.44
Highest qualityLLY79 / 100
Largest discount to fair valueBIIB-2%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
BIIB
stronger →← stronger
LLY
58
Qualityreturns · margins · balance sheet
79
32
Growthrevenue & earnings expansion
97
29
Valuevaluation vs sector peers
60
LLY is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
BIIB
LLY
$2.4bB
FCF
$13.6bA-
+1.2%C
Rev
+49.6%A
0.44B
D/E
1.62C
40.1xC
P/E
39.6xC+
2.25C
PEG
1.13B+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BIIB
LLY
2% below
Price vs fair valuelower is cheaper
234% above
~2%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~48%/yr
+5%
1-yr DCF upside
-77%
+2%
5-yr DCF upside
-70%
-3%
10-yr DCF upside
-56%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BIIB
No notable signals flagged.
LLY
Why this score
Raising its dividend
Durable high returns
The companies
BIIBBiogen Inc.
Drug Manufacturers - General · $225.71 · beta 0.09
Why now
Drug Manufacturers - General · market cap $33.3b. Trading near 52-week high of $230.49 — momentum setup, limited technical margin of safety. 31 sell-side analysts rate this a Buy with a mean 1-yr target of $239.02 (implying +6% upside).
Moat
Net margin 14% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 177% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 7% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
LLYEli Lilly and Company
Drug Manufacturers - General · $1,179.27 · beta 0.45
Why now
Drug Manufacturers - General · market cap $1.1T. 9% off the 52-week high of $1292.65. Revenue growing +50% — in hypergrowth territory. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $1,330 (implying +13% upside).
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 13.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BIIB and LLY diverge
On the headline score the gap is 39.6 points in favor of LLY. The widest single difference is Growth, where LLY leads by 65.1 points.
GrowthBIIB 31.9 · LLY 97.0LLY +65.1
ValueBIIB 29.1 · LLY 60.1LLY +31.0
QualityBIIB 57.7 · LLY 79.2LLY +21.5
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is LLY or BIIB the better stock?
LLY scores higher: LLY 77.3, BIIB 37.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do LLY and BIIB differ most?
The widest gap is growth, where LLY leads by 65 points on the 0–100 pillar scale. LLY leads all three pillars, so the gap is broad rather than a single-measure difference.
How are LLY and BIIB scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.